Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Down 29.4% in August

Key Points

• Short interest in Spectral Diagnostics Inc. decreased by 29.4% in August, totaling 64,600 shares as of August 15th.
• The company's average trading volume is 83,700 shares, resulting in a short-interest ratio of 0.8 days.
• Spectral Diagnostics has a market cap of $334.41 million with a price-to-earnings ratio of -16.71 and a trading price of $1.17 as of Monday.

Spectral Diagnostics Inc. (OTCMKTS:EDTXF - ) saw a large decline in short interest in the month of August. As of August 15th, there was short interest totaling 64,600 shares, adeclineof29.4% from the July 31st total of 91,500 shares. Based on an average trading volume of 83,700 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 83,700 shares, the short-interest ratio is presently 0.8 days.

Spectral Diagnostics Trading Up 1.3%

EDTXF opened at $1.17 on Monday. The company's fifty day moving average price is $0.74 and its two-hundred day moving average price is $0.62. Spectral Diagnostics has a 1-year low of $0.32 and a 1-year high of $1.31. The company has a market cap of $334.41 million, a price-to-earnings ratio of -16.71 and a beta of 0.26.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.